Healthcare / Drug Manufacturers - Specialty & GenericBSE
$776.35
+41.25 (+5.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 18%
FCF escenarios
weak_data · normalized FCF $12.4M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$87.7B
P/E
52.2x
↑EV/EBITDA
44.8x
↑ROE
28.1%
↑Gross Margin
65.4%
↑Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+8.0%
FCF CAGR
—
FCF margin
-3.1%
FCF / Net income
-0.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.97B · net income $1.39B · FCF $-155.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $4.97B | $4.97B | $4.55B | $4.26B |
| Net Income | $1.39B | $1.39B | $1.33B | $623.2M |
| EBITDA | $1.98B | $1.98B | $1.87B | $973.0M |
| EPS | 12.28 | 12.28 | 11.79 | 5.52 |
| Gross Margin | 65.4% | 65.4% | 62.1% | 55.7% |
| Operating Margin | 36.4% | 36.4% | 38.3% | 19.7% |
| Net Margin | 27.9% | 27.9% | 29.3% | 14.6% |
| Balance Sheet | ||||
| Debt/Equity | 0.28 | 0.28 | 0.22 | 0.37 |
| Current Ratio | 3.09 | 3.09 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-155.1M | $-155.1M | $132.2M | $12.4M |
| Returns | ||||
| ROE | 28.1% | 28.1% | 37.4% | 27.9% |
| Valuation | ||||
| P/E | 52.17 | 52.17 | — | — |
| EV/EBITDA | 44.77 | 44.77 | — | — |
| P/B | 17.78 | 17.78 | — | — |
| Growth & Yield | ||||
| Revenue Growth | 9.4% | 9.4% | 6.7% | — |
| EPS Growth | 4.1% | 4.1% | 113.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
77.7%
EPS terminal req.
$68.89
Spread vs growth
-73.6%
5Y implied EPS CAGR
46.7%
EPS terminal req.
$83.35
Spread vs growth
-42.5%
10Y implied EPS CAGR
27.0%
EPS terminal req.
$134.24
Spread vs growth
-22.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.2%
Start / end P/E
65.6x → 63.8x
EPS bridge
11.79 → 12.28
Residual
-0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.